Citation Impact
Citing Papers
ATP-Citrate Lyase Links Cellular Metabolism to Histone Acetylation
2009 StandoutScience
Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
2009 StandoutScience
Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity
2004 StandoutNobel
Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824
2009
Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate
1999
Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents
2015
Drug Insight: histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acid
2005
Role of Transforming Growth Factor β in Human Disease
2000 Standout
Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
2000
HDAC6 is a microtubule-associated deacetylase
2002 StandoutNature
Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)
2002
Autophagy fights disease through cellular self-digestion
2008 StandoutNature
D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA
1992
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia
2001
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
The Human Transcription Factors
2018 Standout
p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21
1994 Standout
Histone deacetylases, transcriptional control, and cancer
2000
Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells
1997
The Epigenomics of Cancer
2007 Standout
Histone Hyperacetylation Induced by Histone Deacetylase Inhibitors Is Not Sufficient to Cause Growth Inhibition in Human Dermal Fibroblasts
2001
Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band
2006
Prospects: Histone deacetylase inhibitors
2005
Epigenetics in Cancer
2008 Standout
Anticancer activities of histone deacetylase inhibitors
2006 Standout
Functional Role of G9a Histone Methyltransferase in Cancer
2015
ICI182,780 Induces p21 Gene Transcription through Releasing Histone Deacetylase 1 and Estrogen Receptor α from Sp1 Sites to Induce Cell Cycle Arrest in MCF-7 Breast Cancer Cell Line
2004
Histone deacetylation in epigenetics: An attractive target for anticancer therapy
2005
Nuclear factor-κB in cancer development and progression
2006 StandoutNature
Histone deacetylase inhibitors: from target to clinical trials
2002
The role of enhancers in cancer
2016
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
1993 Standout
Histone deacetylases and cancer: causes and therapies
2001 Standout
The cell cycle and the retinoblastoma protein family
1994
Increased expression of histone deacetylase 2 is found in human gastric cancer
2005
Potent Prostaglandin A1 Analogs That Suppress Tumor Cell Growth through Induction of p21 and Reduction of Cyclin E
1998 StandoutNobel
Gene Silencing in Cancer in Association with Promoter Hypermethylation
2003 Standout
The Metastasis-associated Proteins 1 and 2 Form Distinct Protein Complexes with Histone Deacetylase Activity
2003
How were new medicines discovered?
2011 Standout
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
1994 StandoutNature
A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types
1994 StandoutScience
Hypoxia Rescues Frataxin Loss by Restoring Iron Sulfur Cluster Biogenesis
2019 StandoutNobel
Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53
1999
G1 phase progression: Cycling on cue
1994 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
E2F-1 Functions in Mice to Promote Apoptosis and Suppress Proliferation
1996 StandoutNobel
limma powers differential expression analyses for RNA-sequencing and microarray studies
2015 Standout
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug
2007
Histone deacetylase inhibitors: molecular mechanisms of action
2007
p21 is a universal inhibitor of cyclin kinases
1993 StandoutNature
Down-regulation of Histone Deacetylases Stimulates Adipocyte Differentiation
2006
Molecular Cloning and Characterization of a Novel Histone Deacetylase HDAC10
2002
Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis
2005
Principles of CDK regulation
1995 StandoutNature
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia
2006
NF-κB and cell-cycle regulation: the cyclin connection
2001
Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells
2009
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
1999 Nature
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Histone deacetylase inhibitors in clinical development
2004
A brain-specific activator of cyclin-dependent kinase 5
1994 StandoutNatureNobel
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
2006 Standout
Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP
2005
Apoptosis Signal-regulating Kinase 1 Is a Direct Target of E2F1 and Contributes to Histone Deacetylase Inhibitorinduced Apoptosis through Positive Feedback Regulation of E2F1 Apoptotic Activity
2006
Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
1994 Standout
TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders
2000 Standout
TGFβ inhibition of Cdk4 synthesis is linked to cell cycle arrest
1993
Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
2013 StandoutNature
γH2Ax: Biomarker of Damage or Functional Participant in DNA Repair “All that Glitters Is not Gold!”
2011
lin-35 and lin-53, Two Genes that Antagonize a C. elegans Ras Pathway, Encode Proteins Similar to Rb and Its Binding Protein RbAp48
1998 StandoutNobel
FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity
2001 StandoutNobel
Inhibition of Nucleotide Excision Repair by the Cyclin-dependent Kinase Inhibitor p21
1995 StandoutNobel
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
1993 StandoutNature
Transcription therapy for cancer
2001
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins
1993 Standout
Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
1994 Standout
Mammalian G1 cyclins
1993 Standout
DNA Repair Synthesis and Ligation Affect the Processing of Excised Oligonucleotides Generated by Human Nucleotide Excision Repair
2014 StandoutNobel
Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy
2004
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
2009 Standout
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
2005
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
2000
Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma.
1999
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma
2003
Cancer Cell Cycles
1996 StandoutScience
Growth-regulated expression of D-type cyclin genes in human diploid fibroblasts.
1992
A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library.
2000
Cell Cycle Control and Cancer
1994 StandoutScienceNobel
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
1998
Cancer Cells Become Susceptible to Natural Killer Cell Killing after Exposure to Histone Deacetylase Inhibitors Due to Glycogen Synthase Kinase-3–Dependent Expression of MHC Class I–Related Chain A and B
2005
Histone Deacetylase Inhibitors Trigger a G2 Checkpoint in Normal Cells That Is Defective in Tumor Cells
2000
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species
2001
Identification of G1 kinase activity for cdk6, a novel cyclin D partner.
1994
Catalytic Asymmetric Hydroalkoxylation of C–C Multiple Bonds
2021 StandoutNobel
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin
2002
Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment.
2002
Histone deacetylase 4 associates with extracellular signal-regulated kinases 1 and 2, and its cellular localization is regulated by oncogenic Ras
2000
Transient Regenerative Potential of the Neonatal Mouse Heart
2011 StandoutScience
Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment
2000
Cyclin D1 is a nuclear protein required for cell cycle progression in G1.
1993
Functional relevance of the histone γH2Ax in the response to DNA damaging agents
2011
The retinoblastoma protein and cell cycle control
1995 Standout
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors
2004
Cyclin A and cyclin B dissociate from p34cdc2 with half-times of 4 and 15 h, respectively, regardless of the phase of the cell cycle.
1994 StandoutNobel
Histone Deacetylase Inhibitors
2003
Novel mechanisms of apoptosis induced by histone deacetylase inhibitors.
2003
Targeted Expression of Cyclin D2 Results in Cardiomyocyte DNA Synthesis and Infarct Regression in Transgenic Mice
2004
Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.
2001
Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death
2005
Methylation of hypoxia-inducible factor (HIF)-1α by G9a/GLP inhibits HIF-1 transcriptional activity and cell migration
2018 StandoutNobel
Histone Deacetylase Inhibitors Down-Regulate bcl-2 Expression and Induce Apoptosis in t(14;18) Lymphomas
2005
Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein.
1994
Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim
2005
p53-dependent repression of CDK4 translation in TGF-beta-induced G1 cell-cycle arrest.
1995
D-type cyclin-dependent kinase activity in mammalian cells.
1994
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
2003
Syntheses of Thailandepsin B Pseudo‐Natural Products: Access to New Highly Potent HDAC Inhibitors via Late‐Stage Modification
2020
Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl–mediated drug resistance
2007
Cyclin D1 Is Dispensable for G1 Control in Retinoblastoma Gene-Deficient Cells Independently of cdk4 Activity
1995
Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas.
1993
A maize cDNA encoding a member of the retinoblastoma protein family: involvement in endoreduplication.
1996 StandoutNobel
Blockade of Histone Deacetylase Inhibitor-Induced RelA/p65 Acetylation and NF-κB Activation Potentiates Apoptosis in Leukemia Cells through a Process Mediated by Oxidative Damage, XIAP Downregulation, and c-Jun N-Terminal Kinase 1 Activation
2005
Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors
2005
Suppression of cyclin-dependent kinase 4 during induced differentiation of erythroleukemia cells.
1994
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia
2001
Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase.
1994
Histone deacetylase inhibitor selectively induces p21 WAF1 expression and gene-associated histone acetylation
2000
Works of Lang Ngo being referenced
Cloning of the cDNA encoding phenylalanyl tRNA synthetase regulatory α-subunit-like protein whose expression is down-regulated during differentiation
1999
Photoaffinity Labeling and Mass Spectrometry Identify Ribosomal Protein S3 as a Potential Target for Hybrid Polar Cytodifferentiation Agents
1999
Changes in p34cdc2 kinase activity and cyclin A during induced differentiation of murine erythroleukemia cells.
1992
Cloning of a D-type cyclin from murine erythroleukemia cells.
1992
Histone deacetylase inhibitors selectively suppress expression of HDAC7
2007
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
2010
Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor
2006
Histone deacetylase (HDAC) inhibitor activation of p21 WAF1 involves changes in promoter-associated proteins, including HDAC1
2004
Induction of Polyploidy by Histone Deacetylase Inhibitor: A Pathway for Antitumor Effects
2005
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors
2005
Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.
1996
Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents
2010
Potent cytodifferentiating agents related to hexamethylenebisacetamide.
1991